Yuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuan Liu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Dong Li
State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Academy of Military Medical Sciences , Beijing 102206
7 shared publications Lihong Diao
State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Academy of Military Medical Sciences, Beijing, China
4 shared publications- Dianke Li
State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, China
3 shared publications - Xun Wang
Laboratory of Cardiovascular Science, Beijing Clinical Research Institute (K.Z., J.G., Y. Liu, J.L., X.W., R.D., L.G., J.B., R.C., Z.L., W.Z., Y.Z., Y.W., L.D., Y. Li, D.-S.L., W.A., C.-M.C.), Beijing Friendship Hospital, Capital Medical University, China
3 shared publications - Yang Li
State Key Laboratory of Medical Proteomics Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences and Peking Union Medical College) National Center for Protein Sciences (Beijing), Beijing 102206
3 shared publications - Zhongyang Liu
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics , Beijing 102206 , China
3 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
UbiBrowser 3.0: towards comprehensively characterizing human ubiquitin ligase–substrate interactions by incorporating ubiquitin chain information
Ubiquitination is a crucial post-translational modification, whose functional diversity is largely determined by the structures of ubiquitin (Ub) chains. The specific interaction between E3 ubiquitin ligases and substrates (ESIs) precisely regulates Ub chain assembly, directing substrates toward different fates like degradation or signaling. In 2022, we released UbiBrowser 2.0, containing known/predicted ESIs and deubiquitinase–substrate interactions from 39 species. To address the urgent need for in-depth analysis of Ub chain functions, we updated UbiBrowser to v3.0 (http://ubibrowser.ncpsb.org.cn). This upgrade integrates a comprehensive framework linking ESIs, Ub chain types, and cellular effects. This includes 776 experimentally verified ESI–Ub chain type associations, covering 8 Ub chain types and 15 cellular effects categories, more precisely characterizing human ESIs, and expanding the collection of known ESIs in UbiBrowser to 4300 unique pairs. Furthermore, building upon the original functionalities, the website introduces novel Ub chain-centric modules: (i) Ub Chain-Centric Interaction Explorer: integrates network graphs, tables, and evidence to display the relationships among ESIs, chain types, and cellular effects; (ii) Ub Chain-Centric Interaction Browser: provides bidirectional browsing of E3s/substrates based on a Ub chain type classification tree. UbiBrowser 3.0 will facilitate a deeper understanding of the complex regulatory mechanisms of ubiquitination and support hypothesis generation on Ub chain type-dependent regulation of substrate fate and protein function.
- 13 October 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
Open AccessUbiBrowser 3.0: towards comprehensively characterizing human ubiquitin ligase–substrate interactions by incorporating ubiquitin chain information
Ubiquitination is a crucial post-translational modification, whose functional diversity is largely determined by the structures of ubiquitin (Ub) chains. The specific interaction between E3 ubiquitin ligases and substrates (ESIs) precisely regulates Ub chain assembly, directing substrates toward different fates like degradation or signaling. In 2022, we released UbiBrowser 2.0, containing known/predicted ESIs and deubiquitinase–substrate interactions from 39 species. To address the urgent need for in-depth analysis of Ub chain functions, we updated UbiBrowser to v3.0 (http://ubibrowser.ncpsb.org.cn). This upgrade integrates a comprehensive framework linking ESIs, Ub chain types, and cellular effects. This includes 776 experimentally verified ESI–Ub chain type associations, covering 8 Ub chain types and 15 cellular effects categories, more precisely characterizing human ESIs, and expanding the collection of known ESIs in UbiBrowser to 4300 unique pairs. Furthermore, building upon the original functionalities, the website introduces novel Ub chain-centric modules: (i) Ub Chain-Centric Interaction Explorer: integrates network graphs, tables, and evidence to display the relationships among ESIs, chain types, and cellular effects; (ii) Ub Chain-Centric Interaction Browser: provides bidirectional browsing of E3s/substrates based on a Ub chain type classification tree. UbiBrowser 3.0 will facilitate a deeper understanding of the complex regulatory mechanisms of ubiquitination and support hypothesis generation on Ub chain type-dependent regulation of substrate fate and protein function.
- Open Access
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Interpretable deep learning framework for mapping E3–substrate binding interfaces
E3 ubiquitin ligases recognize substrates through specific interfaces. Accurate delineation of these interfaces is essential, as mutations disrupting them impair protein ubiquitination and drive cancer progression. However, available E3-substrate interface data are sparse and systematic prediction methods remain lacking. Here, we propose MetaESI, a deep learning framework that simultaneously predicts E3-substrate interactions and leverages its interpretable architecture to infer binding interfaces de novo. With a two-stage meta-learning strategy, MetaESI generalizes across diverse E3s and achieves state-of-the-art performance in both interaction and interface prediction. We applied MetaESI at the proteome scale to generate MetaESI-Atlas, which comprises 68,056 annotated interactions across eight species. Integrating multi-omics data, we identified mutations at MetaESI-predicted interfaces that disrupt E3-substrate binding, and experimentally validated representative examples including JunB Q244E and SPOP F102C as oncogenic drivers. By combining interpretable AI with mechanistic insight, MetaESI establishes a methodological paradigm for interpretable model design and a foundational resource for precision oncology and targeted protein degradation.
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessInterpretable deep learning framework for mapping E3–substrate binding interfaces
E3 ubiquitin ligases recognize substrates through specific interfaces. Accurate delineation of these interfaces is essential, as mutations disrupting them impair protein ubiquitination and drive cancer progression. However, available E3-substrate interface data are sparse and systematic prediction methods remain lacking. Here, we propose MetaESI, a deep learning framework that simultaneously predicts E3-substrate interactions and leverages its interpretable architecture to infer binding interfaces de novo. With a two-stage meta-learning strategy, MetaESI generalizes across diverse E3s and achieves state-of-the-art performance in both interaction and interface prediction. We applied MetaESI at the proteome scale to generate MetaESI-Atlas, which comprises 68,056 annotated interactions across eight species. Integrating multi-omics data, we identified mutations at MetaESI-predicted interfaces that disrupt E3-substrate binding, and experimentally validated representative examples including JunB Q244E and SPOP F102C as oncogenic drivers. By combining interpretable AI with mechanistic insight, MetaESI establishes a methodological paradigm for interpretable model design and a foundational resource for precision oncology and targeted protein degradation.
- Open Access
- 23 May 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25  (4)
Integration of protein sequence and protein–protein interaction data by hypergraph learning to identify novel protein complexes
Protein–protein interactions (PPIs) are the basis of many important biological processes, with protein complexes being the key forms implementing these interactions. Understanding protein complexes and their functions is critical for elucidating mechanisms of life processes, disease diagnosis and treatment and drug development. However, experimental methods for identifying protein complexes have many limitations. Therefore, it is necessary to use computational methods to predict protein complexes. Protein sequences can indicate the structure and biological functions of proteins, while also determining their binding abilities with other proteins, influencing the formation of protein complexes. Integrating these characteristics to predict protein complexes is very promising, but currently there is no effective framework that can utilize both protein sequence and PPI network topology for complex prediction. To address this challenge, we have developed HyperGraphComplex, a method based on hypergraph variational autoencoder that can capture expressive features from protein sequences without feature engineering, while also considering topological properties in PPI networks, to predict protein complexes. Experiment results demonstrated that HyperGraphComplex achieves satisfactory predictive performance when compared with state-of-art methods. Further bioinformatics analysis shows that the predicted protein complexes have similar attributes to known ones. Moreover, case studies corroborated the remarkable predictive capability of our model in identifying protein complexes, including 3 that were not only experimentally validated by recent studies but also exhibited high-confidence structural predictions from AlphaFold-Multimer. We believe that the HyperGraphComplex algorithm and our provided proteome-wide high-confidence protein complex prediction dataset will help elucidate how proteins regulate cellular processes in the form of complexes, and facilitate disease diagnosis and treatment and drug development. Source codes are available at https://github.com/LiDlab/HyperGraphComplex.
- 23 May 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25  (4)
Open AccessIntegration of protein sequence and protein–protein interaction data by hypergraph learning to identify novel protein complexes
Protein–protein interactions (PPIs) are the basis of many important biological processes, with protein complexes being the key forms implementing these interactions. Understanding protein complexes and their functions is critical for elucidating mechanisms of life processes, disease diagnosis and treatment and drug development. However, experimental methods for identifying protein complexes have many limitations. Therefore, it is necessary to use computational methods to predict protein complexes. Protein sequences can indicate the structure and biological functions of proteins, while also determining their binding abilities with other proteins, influencing the formation of protein complexes. Integrating these characteristics to predict protein complexes is very promising, but currently there is no effective framework that can utilize both protein sequence and PPI network topology for complex prediction. To address this challenge, we have developed HyperGraphComplex, a method based on hypergraph variational autoencoder that can capture expressive features from protein sequences without feature engineering, while also considering topological properties in PPI networks, to predict protein complexes. Experiment results demonstrated that HyperGraphComplex achieves satisfactory predictive performance when compared with state-of-art methods. Further bioinformatics analysis shows that the predicted protein complexes have similar attributes to known ones. Moreover, case studies corroborated the remarkable predictive capability of our model in identifying protein complexes, including 3 that were not only experimentally validated by recent studies but also exhibited high-confidence structural predictions from AlphaFold-Multimer. We believe that the HyperGraphComplex algorithm and our provided proteome-wide high-confidence protein complex prediction dataset will help elucidate how proteins regulate cellular processes in the form of complexes, and facilitate disease diagnosis and treatment and drug development. Source codes are available at https://github.com/LiDlab/HyperGraphComplex.
- Open Access
- 20 October 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50  (D1) , D719-D728
UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase/deubiquitinase–substrate interactions in eukaryotic species
As an important post-translational modification, ubiquitination mediates ∼80% of protein degradation in eukaryotes. The degree of protein ubiquitination is tightly determined by the delicate balance between specific ubiquitin ligase (E3)-mediated ubiquitination and deubiquitinase-mediated deubiquitination. In 2017, we developed UbiBrowser 1.0, which is an integrated database for predicted human proteome-wide E3–substrate interactions. Here, to meet the urgent requirement of proteome-wide E3/deubiquitinase–substrate interactions (ESIs/DSIs) in multiple organisms, we updated UbiBrowser to version 2.0 (http://ubibrowser.ncpsb.org.cn). Using an improved protocol, we collected 4068/967 known ESIs/DSIs by manual curation, and we predicted about 2.2 million highly confident ESIs/DSIs in 39 organisms, with >210-fold increase in total data volume. In addition, we made several new features in the updated version: (i) it allows exploring proteins’ upstream E3 ligases and deubiquitinases simultaneously; (ii) it has significantly increased species coverage; (iii) it presents a uniform confidence scoring system to rank predicted ESIs/DSIs. To facilitate the usage of UbiBrowser 2.0, we also redesigned the web interface for exploring these known and predicted ESIs/DSIs, and added functions of ‘Browse’, ‘Download’ and ‘Application Programming Interface’. We believe that UbiBrowser 2.0, as a discovery tool, will contribute to the study of protein ubiquitination and the development of drug targets for complex diseases.
- 20 October 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50  (D1) , D719-D728
Open AccessUbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase/deubiquitinase–substrate interactions in eukaryotic species
As an important post-translational modification, ubiquitination mediates ∼80% of protein degradation in eukaryotes. The degree of protein ubiquitination is tightly determined by the delicate balance between specific ubiquitin ligase (E3)-mediated ubiquitination and deubiquitinase-mediated deubiquitination. In 2017, we developed UbiBrowser 1.0, which is an integrated database for predicted human proteome-wide E3–substrate interactions. Here, to meet the urgent requirement of proteome-wide E3/deubiquitinase–substrate interactions (ESIs/DSIs) in multiple organisms, we updated UbiBrowser to version 2.0 (http://ubibrowser.ncpsb.org.cn). Using an improved protocol, we collected 4068/967 known ESIs/DSIs by manual curation, and we predicted about 2.2 million highly confident ESIs/DSIs in 39 organisms, with >210-fold increase in total data volume. In addition, we made several new features in the updated version: (i) it allows exploring proteins’ upstream E3 ligases and deubiquitinases simultaneously; (ii) it has significantly increased species coverage; (iii) it presents a uniform confidence scoring system to rank predicted ESIs/DSIs. To facilitate the usage of UbiBrowser 2.0, we also redesigned the web interface for exploring these known and predicted ESIs/DSIs, and added functions of ‘Browse’, ‘Download’ and ‘Application Programming Interface’. We believe that UbiBrowser 2.0, as a discovery tool, will contribute to the study of protein ubiquitination and the development of drug targets for complex diseases.
- Open Access
- 27 September 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50  (D1) , D1184-D1199
CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response
To date, only some cancer patients can benefit from chemotherapy and targeted therapy. Drug resistance continues to be a major and challenging problem facing current cancer research. Rapidly accumulated patient-derived clinical transcriptomic data with cancer drug response bring opportunities for exploring molecular determinants of drug response, but meanwhile pose challenges for data management, integration, and reuse. Here we present the Cancer Treatment Response gene signature DataBase (CTR-DB, http://ctrdb.ncpsb.org.cn/), a unique database for basic and clinical researchers to access, integrate, and reuse clinical transcriptomes with cancer drug response. CTR-DB has collected and uniformly reprocessed 83 patient-derived pre-treatment transcriptomic source datasets with manually curated cancer drug response information, involving 28 histological cancer types, 123 drugs, and 5139 patient samples. These data are browsable, searchable, and downloadable. Moreover, CTR-DB supports single-dataset exploration (including differential gene expression, receiver operating characteristic curve, functional enrichment, sensitizing drug search, and tumor microenvironment analyses), and multiple-dataset combination and comparison, as well as biomarker validation function, which provide insights into the drug resistance mechanism, predictive biomarker discovery and validation, drug combination, and resistance mechanism heterogeneity.
- 27 September 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50  (D1) , D1184-D1199
Open AccessCTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response
To date, only some cancer patients can benefit from chemotherapy and targeted therapy. Drug resistance continues to be a major and challenging problem facing current cancer research. Rapidly accumulated patient-derived clinical transcriptomic data with cancer drug response bring opportunities for exploring molecular determinants of drug response, but meanwhile pose challenges for data management, integration, and reuse. Here we present the Cancer Treatment Response gene signature DataBase (CTR-DB, http://ctrdb.ncpsb.org.cn/), a unique database for basic and clinical researchers to access, integrate, and reuse clinical transcriptomes with cancer drug response. CTR-DB has collected and uniformly reprocessed 83 patient-derived pre-treatment transcriptomic source datasets with manually curated cancer drug response information, involving 28 histological cancer types, 123 drugs, and 5139 patient samples. These data are browsable, searchable, and downloadable. Moreover, CTR-DB supports single-dataset exploration (including differential gene expression, receiver operating characteristic curve, functional enrichment, sensitizing drug search, and tumor microenvironment analyses), and multiple-dataset combination and comparison, as well as biomarker validation function, which provide insights into the drug resistance mechanism, predictive biomarker discovery and validation, drug combination, and resistance mechanism heterogeneity.
- Open Access
- 14 April 2021
- Published by Springer Nature in Research Square
DCABM-TCM, a Database of Constituents Absorbed into Blood and Metabolites of Traditional Chinese Medicine
Traditional Chinese Medicine (TCM) not only maintains the health of peoples in Asia but also provides a great resource of active natural products for modern drug development. However, owing to its diverse constituents and the complex interactions with the human body, it is still challenging to clarify its effective constituents and molecular mechanism. This greatly hinders its widespread application worldwide and TCM-based modern drug development. The vast majority of constituents in TCM can produce pharmacological effects only after they are absorbed into bloodstream. Compared with ordinary constituents generally detected in vitro, these that are verified to reach the bloodstream, including original constituents absorbed into blood and metabolites of original constituents produced by the gastrointestinal tract, intestinal microflora, and liver, are more likely to be really effective ones responsible for the pharmacological effects. Here we developed DCABM-TCM (a Database of Constituents Absorbed into Blood and Metabolites of TCM), the first database systematically collecting blood constituents of TCM prescriptions and herbs, including prototypes and metabolites experimentally-detected in blood, together with the corresponding detailed detection conditions by manual literature mining. Currently DCABM-TCM has collected 4206 blood constituents of 192 prescriptions and 194 herbs, and also integrated various related annotations including physicochemical properties, ADMET properties, and associated targets, functional terms, pathways, and diseases etc. Furthermore, DCABM-TCM supported two analysis functions, the network pharmacology analysis for TCM molecular mechanism elucidation and the target/pathway/disease-based screening of candidate blood constituents, herbs or prescriptions for TCM-based drug discovery. DCABM-TCM is freely assessable by http://bionet.ncpsb.org.cn/dcabm-tcm/ and is browsable and searchable for each of 6 kinds of entities, including prescriptions, herbs, blood constituents, targets, pathways, and diseases. DCABM-TCM will contribute to not only the elucidation of effective constituents and molecular mechanism of TCMs but also the discovery of TCM-derived drug-like compounds which are both bioactive and bioavailable, the feature investigation of absorbable natural compounds, and the quality control of herbs.
- 14 April 2021
- Published by Springer Nature in Research Square
Open AccessDCABM-TCM, a Database of Constituents Absorbed into Blood and Metabolites of Traditional Chinese Medicine
Traditional Chinese Medicine (TCM) not only maintains the health of peoples in Asia but also provides a great resource of active natural products for modern drug development. However, owing to its diverse constituents and the complex interactions with the human body, it is still challenging to clarify its effective constituents and molecular mechanism. This greatly hinders its widespread application worldwide and TCM-based modern drug development. The vast majority of constituents in TCM can produce pharmacological effects only after they are absorbed into bloodstream. Compared with ordinary constituents generally detected in vitro, these that are verified to reach the bloodstream, including original constituents absorbed into blood and metabolites of original constituents produced by the gastrointestinal tract, intestinal microflora, and liver, are more likely to be really effective ones responsible for the pharmacological effects. Here we developed DCABM-TCM (a Database of Constituents Absorbed into Blood and Metabolites of TCM), the first database systematically collecting blood constituents of TCM prescriptions and herbs, including prototypes and metabolites experimentally-detected in blood, together with the corresponding detailed detection conditions by manual literature mining. Currently DCABM-TCM has collected 4206 blood constituents of 192 prescriptions and 194 herbs, and also integrated various related annotations including physicochemical properties, ADMET properties, and associated targets, functional terms, pathways, and diseases etc. Furthermore, DCABM-TCM supported two analysis functions, the network pharmacology analysis for TCM molecular mechanism elucidation and the target/pathway/disease-based screening of candidate blood constituents, herbs or prescriptions for TCM-based drug discovery. DCABM-TCM is freely assessable by http://bionet.ncpsb.org.cn/dcabm-tcm/ and is browsable and searchable for each of 6 kinds of entities, including prescriptions, herbs, blood constituents, targets, pathways, and diseases. DCABM-TCM will contribute to not only the elucidation of effective constituents and molecular mechanism of TCMs but also the discovery of TCM-derived drug-like compounds which are both bioactive and bioavailable, the feature investigation of absorbable natural compounds, and the quality control of herbs.
- 13 May 2019
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 95  (8) , 1172-1177
UVGD 1.0: a gene-centric database bridging ultraviolet radiation and molecular biology effects in organisms
Objectives: Exposing to ultraviolet for a certain time will trigger some significant molecular biology effects in an organism. In the past few decades, varied ultraviolet-associated biological effects as well as their related genes, have been discovered under biologists’ efforts. However, information about ultraviolet-related genes is dispersed in thousands of scientific papers, and there is still no study emphasizing on the systematic collection of ultraviolet-related genes. Methods: We collected ultraviolet-related genes and built this gene-centric database UVGD based on literature mining and manual curation. Literature mining was based on the ultraviolet-related abstracts downloaded from PubMed, and we obtained sentences in which ultraviolet keywords and genes co-occur at single-sentence level by using bio-entity recognizer. After that, manual curation was implemented in order to identify whether the genes are related to ultraviolet or not. Results: we built the ultraviolet-related knowledge base UVGD 1.0 (URL: http://biokb.ncpsb.org/UVGD/), which contains 663 ultraviolet-related genes, together with 17 associated biological processes, 117 associated phenotypes and 929 MeSH terms. Conclusion: UVGD is helpful to understand the ultraviolet-related biological processes in organisms and we believe it would be useful for biologists to study the responding mechanisms to ultraviolet.
- 13 May 2019
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 95  (8) , 1172-1177
UVGD 1.0: a gene-centric database bridging ultraviolet radiation and molecular biology effects in organisms
Objectives: Exposing to ultraviolet for a certain time will trigger some significant molecular biology effects in an organism. In the past few decades, varied ultraviolet-associated biological effects as well as their related genes, have been discovered under biologists’ efforts. However, information about ultraviolet-related genes is dispersed in thousands of scientific papers, and there is still no study emphasizing on the systematic collection of ultraviolet-related genes. Methods: We collected ultraviolet-related genes and built this gene-centric database UVGD based on literature mining and manual curation. Literature mining was based on the ultraviolet-related abstracts downloaded from PubMed, and we obtained sentences in which ultraviolet keywords and genes co-occur at single-sentence level by using bio-entity recognizer. After that, manual curation was implemented in order to identify whether the genes are related to ultraviolet or not. Results: we built the ultraviolet-related knowledge base UVGD 1.0 (URL: http://biokb.ncpsb.org/UVGD/), which contains 663 ultraviolet-related genes, together with 17 associated biological processes, 117 associated phenotypes and 929 MeSH terms. Conclusion: UVGD is helpful to understand the ultraviolet-related biological processes in organisms and we believe it would be useful for biologists to study the responding mechanisms to ultraviolet.